These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22027293)

  • 1. Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same?
    Heinemann L; Steiner S
    J Diabetes Sci Technol; 2011 Sep; 5(5):1027-9. PubMed ID: 22027293
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraperitoneal insulin therapy for a patient with type 1 diabetes with insulin injection site inflammation.
    Lee SI; Narendran P
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25188930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption kinetics of insulin after subcutaneous administration.
    Søeborg T; Rasmussen CH; Mosekilde E; Colding-Jørgensen M
    Eur J Pharm Sci; 2009 Jan; 36(1):78-90. PubMed ID: 19028573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations to subcutaneous insulin administration in type 1 diabetes.
    Chen JW; Christiansen JS; Lauritzen T
    Diabetes Obes Metab; 2003 Jul; 5(4):223-33. PubMed ID: 12795655
    [No Abstract]   [Full Text] [Related]  

  • 6. What are the disadvantages of sliding-scale insulin?
    Michota F
    J Hosp Med; 2007; 2 Suppl 1():20-2. PubMed ID: 17311240
    [No Abstract]   [Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion--an historical perspective.
    Skyler JS
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S5-9. PubMed ID: 20515307
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.
    Rave K; Potocka E; Heinemann L; Heise T; Boss AH; Marino M; Costello D; Chen R
    Diabetes Obes Metab; 2009 Jul; 11(7):715-20. PubMed ID: 19476477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements?
    Heinemann L
    J Diabetes Sci Technol; 2009 Nov; 3(6):1490-500. PubMed ID: 20144405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary insulin administration using the AERx insulin diabetes system.
    Thipphawong J; Otulana B; Clauson P; Okikawa J; Farr SJ
    Diabetes Technol Ther; 2002; 4(4):499-504. PubMed ID: 12396744
    [No Abstract]   [Full Text] [Related]  

  • 11. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
    Muchmore DB; Vaughn DE
    J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term clinical application of wearable artificial endocrine pancreas].
    Konno Y; Nishida K; Shimoda S; Sakakida M; Shichiri M
    Nihon Rinsho; 1997 Nov; 55 Suppl():282-7. PubMed ID: 9434481
    [No Abstract]   [Full Text] [Related]  

  • 13. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prolonged release microcapsules of insulin for complement of the basal secretion].
    Ogawa Y; Takenaga M; Yamaguchi Y; Igarashi R; Mizushima Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():542-7. PubMed ID: 12387048
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes.
    Kapitza C; Zijlstra E; Heinemann L; Castelli MC; Riley G; Heise T
    Diabetes Care; 2010 Jun; 33(6):1288-90. PubMed ID: 20185734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.
    Kim D; Mudaliar S; Chinnapongse S; Chu N; Boies SM; Davis T; Perera AD; Fishman RS; Shapiro DA; Henry R
    Diabetes Care; 2003 Oct; 26(10):2842-7. PubMed ID: 14514589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model.
    Radziuk JM; Davies JC; Pye WS; Shields JE; DiMarchi RD; Chance RE
    Diabetes; 1997 Apr; 46(4):548-56. PubMed ID: 9075793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid hyperglycemia.
    Khurana A; Vinayek N
    J Hosp Med; 2007 Jul; 2(4):285; author reply 285-6. PubMed ID: 17705218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.